RxDoctor Payments Data

Jean Luc Franck, MD

Nephrology · Vero Beach, FLNPI 1992128482

Payments from drug & device makers

$641in general payments, 2019–2025

Across 13 payments — averaging $49.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$169
  • Otsuka America Pharmaceutical, Inc.$124
  • Nxstage Medical, Inc.$120
  • AstraZeneca$112
  • Baxter Healthcare$92
  • Vifor Pharma, Inc.$24

What the payments were for

  • Food & beverage$57990%
  • Education$6110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$641 in reported general payments places this provider in the 30th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$372,062
Medicare patients
648
Services billed
3,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol56$49,987
JardianceEmpagliflozin27$34,994
OzempicSemaglutide16$13,251
MounjaroTirzepatide15$13,076
LokelmaSodium Zirconium Cyclosilicate12$11,109
RybelsusSemaglutide12$10,831
Sevelamer Carbonate26$9,125
Bumetanide57$5,248
Clonidine35$4,087
Potassium Chloride50$3,767
Nifedipine ErNifedipine53$3,692
Calcium Acetate47$3,537
Potassium Citrate ErPotassium Citrate28$2,453
Furosemide299$2,050
SpsSodium Polystyrene Sulfon/Sorb14$1,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$112$61,09668 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 756 nephrology providers in Florida.

Other nephrology in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →